Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Saitou, N., & Nei, M. (1987) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a040454 · Cited by 59,959

MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms

Kumar, S., Stecher, G., Li, M., Knyaz, C., & Tamura, K. (2018) · Molecular Biology and Evolution · doi:10.1093/molbev/msy096 · Cited by 37,683

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

From local explanations to global understanding with explainable AI for trees

Lundberg, S. M., Erion, G., Chen, H., DeGrave, A., Prutkin, J. M., Nair, B., Katz, R., Himmelfarb, J., Bansal, N., & Lee, S.-I. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-019-0138-9 · Cited by 10,551

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

Origin and evolution of pathogenic coronaviruses

Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729

Prospects for inferring very large phylogenies by using the neighbor-joining method

Tamura, K., Nei, M., & Kumar, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404206101 · Cited by 5,588

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405

Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program

Goudsmit, J., van den Biggelaar, A. H. J., Koudstaal, W., Albert Hofman, D., Koff, W. C., Schenkelberg, T., Alter, G., Mina, M. J., & Wu, J. W. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00767-z · Cited by 22

DNA Vaccine Administered by Cationic Lipoplexes or by In Vivo Electroporation Induces Comparable Antibody Responses against SARS-CoV-2 in Mice

Peletta, A., Prompetchara, E., Tharakhet, K., Kaewpang, P., Buranapraditkun, S., Techawiwattanaboon, T., Jbilou, T., Krangvichian, P., Sirivichayakul, S., Manopwisedjaroen, S., et al. (2021) · Vaccines · doi:10.3390/vaccines9080874 · Cited by 22

Immunodominant and Neutralizing Linear B-Cell Epitopes Spanning the Spike and Membrane Proteins of Porcine Epidemic Diarrhea Virus

Polyiam, K., Ruengjitchatchawalya, M., Mekvichitsaeng, P., Kaeoket, K., Hoonsuwan, T., Joiphaeng, P., & Roshorm, Y. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785293 · Cited by 23

Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination

Wilkins, D. E., Aksyuk, A. A., Ruzin, A. V., Tuffy, K. M., Green, T., Greway, R., Fikes, B., Bonhomme, C. J., Esser, M. T., & Kelly, E. J. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1385 · Cited by 23

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity

Søraas, A. V. L., Grødeland, G., Granerud, B. K., Ueland, T., Lind, A., Fevang, B., Murphy, S. L., Huse, C., Nygaard, A. B., Steffensen, A. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964525 · Cited by 22

Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals

Jaago, M., Rähni, A., Pupina, N., Pihlak, A., Sadam, H., Tuvikene, J., Avarlaid, A., Planken, A., Planken, M., Haring, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20849-6 · Cited by 23

NK cells in COVID-19—from disease to vaccination

Hammer, Q., Cuapio, A., Bister, J., Björkström, N. K., & Ljunggren, H. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad031 · Cited by 25

Identification of Highly Conserved SARS-CoV-2 Antigenic Epitopes with Wide Coverage Using Reverse Vaccinology Approach

Hisham, Y., Ashhab, Y., Hwang, S., & Kim, D. (2021) · Viruses · doi:10.3390/v13050787 · Cited by 22

Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination

Breznik, J. A., Huynh, A., Zhang, A., Bilaver, L., Bhakta, H., Stacey, H. D., Ang, J. C., Bramson, J. L., Nazy, I., Miller, M. S., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200369 · Cited by 23

“Original antigenic sin”: A potential threat beyond the development of booster vaccination against novel SARS-CoV-2 variants

Noori, M., Nejadghaderi, S. A., & Rezaei, N. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.199 · Cited by 22

Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2–infected individuals reveal unlinked immune signatures

Ravichandran, S., Grubbs, G., Tang, J., Lee, Y., Huang, C., Golding, H., & Khurana, S. (2021) · Science Advances · doi:10.1126/sciadv.abi6533 · Cited by 22

SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display

Ehling, R. A., Weber, C. R., Mason, D. M., Friedensohn, S., Wagner, B., Bieberich, F., Kapetanovic, E., Vazquez-Lombardi, R., Roberto, R. B. D., Hong, K., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110242 · Cited by 27

Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients

Farheen, S., Agrawal, S., Zubair, S., Agrawal, A., Jamal, F., Altaf, I., Anwar, A. K., Umair, S. M., & Owais, M. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.748591 · Cited by 23

Human Cytomegalovirus Infection of Epithelial Cells Increases SARS-CoV-2 Superinfection by Upregulating the ACE2 Receptor

Perera, M. R., Greenwood, E. J. D., Crozier, T. W. M., Elder, E., Schmitt, J., Crump, C. M., Lehner, P. J., Wills, M. R., Sinclair, J. H., Baker, S. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac452 · Cited by 22

Massively-multiplexed epitope mapping techniques for viral antigen discovery

Hu, D., & Irving, A. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192385 · Cited by 23

Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2

Chouchane, L., Grivel, J., Farag, E., Pavlovski, I., Maacha, S., Sathappan, A., Al‐Romaihi, H. E., Abuaqel, S. W. J., Ata, M. M. A., Chouchane, A. I., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145785 · Cited by 21

The SARS-CoV-2 antibody landscape is lower in magnitude for structural proteins, diversified for accessory proteins and stable long-term in childrenPreprint

Hachim, A., Gu, H., Kavian, O., Kwan, M. Y. W., Chan, W. H., Yau, Y. S., Chiu, S. S. S., Tsang, O. T., Hui, D. S. C., Ma, F. N. L., et al. (2021) · medRxiv · doi:10.1101/2021.01.03.21249180 · Cited by 22

Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

Kyei-Barffour, I., Akwetey, S. A., Aninagyei, E., Ghartey‐Kwansah, G., & Acheampong, D. O. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112282 · Cited by 21

Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (CoVRapid CL-MIA)

Klüpfel, J., Koros, R. C., Dehne, K., Ungerer, M., Würstle, S. M., Mautner, J., Feuerherd, M., Protzer, U., Hayden, O., Elsner, M., et al. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03315-6 · Cited by 20

Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel

Ng, K. W., Faulkner, N., Wrobel, A. G., Gamblin, S. J., & Kassiotis, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101507 · Cited by 19

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

Gordon, O. M., Brosnan, M. K., Yoon, S., Jung, D., Littlefield, K. E., Ganesan, A., Caputo, C. A., Li, M., Morgenlander, W. R., Henson, S. N., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151518 · Cited by 19

COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins

Elko, E. A., Nelson, G. A., Mead, H., Kelley, E., Carvalho, S. T., Sarbo, N., Harms, C. E., Verche, V. L., Cardoso, A. A., Ely, J. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111022 · Cited by 21

Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June–July 2021)

Matveeva, O. V., & Ershov, A. (2022) · Vaccines · doi:10.3390/vaccines10070984 · Cited by 19

An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells

Nicolas, A., Sannier, G., Dubé, M., Nayrac, M., Tauzin, A., Painter, M. M., Goel, R. R., Laporte, M., Gendron‐Lepage, G., Medjahed, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105904 · Cited by 20

Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy

López-Muñoz, A. D., Santos, J. J. D. S., & Yewdell, J. W. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304087120 · Cited by 22

Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants

Cui, L., Li, T., Xue, W., Zhang, S., Wang, H., Liu, H., Gu, Y., Xia, N., & Li, S. (2024) · Viruses · doi:10.3390/v16060900 · Cited by 18

Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months

Serwanga, J., Ankunda, V., Sembera, J., Kato, L., Oluka, G. K., Baine, C., Odoch, G., Kayiwa, J. T., Auma, B. O., Jjuuko, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152522 · Cited by 20

Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages

Chernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37972-1 · Cited by 17

Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies

Reinig, S., & Shih, S. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100666 · Cited by 22

SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition

Altmann, D. M., Reynolds, C. J., & Boyton, R. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100286 · Cited by 19

CRISPR-based peptide library display and programmable microarray self-assembly for rapid quantitative protein binding assays

Barber, K. W., Shrock, E. L., & Elledge, S. J. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.027 · Cited by 18

Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore

Wang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19

Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization

McConnell, S. A., Sachithanandham, J., Mudrak, N. J., Zhu, X., Farhang, P. A., Cordero, R. J. B., Wear, M. P., Shapiro, J. R., Park, H.-S., Klein, S. L., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.011 · Cited by 17

Defining and Studying B Cell Receptor and TCR Interactions

Rappazzo, C. G., Fernández‐Quintero, M. L., Mayer, A., Wu, N. C., Greiff, V., & Guthmiller, J. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300136 · Cited by 18

Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2

Tarabini, R. F., Rigo, M., Fonseca, A. F., Rubin, F. P., Belle, R. L., Kavraki, L. E., Ferreto, T. C., Antunes, D. A., & de Souza, A. P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.812176 · Cited by 16

Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19

Peddireddy, S. P., Rahman, S. A., Cillo, A. R., Vijay, G. K. M., Somasundaram, A., Workman, C. J., Bain, W., McVerry, B. J., Methé, B. A., Lee, J. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111020 · Cited by 19

Temporal Associations of B and T Cell Immunity with Robust Vaccine Responsiveness in a 16-Week Interval BNT162B2 Regimen

Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N., Lima-Barbosa, R., Beaudoin-Bussières, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111013 · Cited by 17

Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccinationPreprint

Kim, W., Zhou, J. Q., Sturtz, A. J., Horvath, S. C., Schmitz, A. J., Lei, T., Kalaidina, E., Thapa, M., Alsoussi, W. B., Haile, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.31.466651 · Cited by 18

Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada

Tanunliong, G., Liu, A. C., Kaweski, S. E., Irvine, M. A., Reyes, R. C., Purych, D., Krajden, M., Morshed, M. G., Sekirov, I., Gantt, S. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836449 · Cited by 17

A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa

Rahbar, M. R., Mubarak, S. M. H., Hessami, A., Khalesi, B., Pourzardosht, N., Khalili, S., Zanoos, K. A., & Jahangiri, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-14877-5 · Cited by 17

Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis

Ruiz, M. J., Siracusano, G., Cottignies-Calamarte, A., Tudor, D., Real, F., Zhu, A., Pastori, C., Capron, C., Rosenberg, A. R., Temperton, N. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842468 · Cited by 21

The landscape of antibody binding in SARS-CoV-2 infectionPreprint

Heffron, A. S., McIlwain, S. J., Amjadi, M. F., Baker, D. A., Khullar, S., Sethi, A. K., Palmenberg, A. C., Shelef, M. A., O’Connor, D. H., & Ong, I. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.10.334292 · Cited by 16

Pan-viral serology uncovers distinct virome patterns as risk predictors of hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Do, W. L., Wang, L., Forgues, M., Liu, J., Rabibhadana, S., Pupacdi, B., Zhao, Y., Gholian, H., Bhudhisawasdi, V., Pairojkul, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101328 · Cited by 16

Precision arbovirus serology with a pan-arbovirus peptidome

Morgenlander, W. R., Chia, W. N., Parra, B., Monaco, D. R., Ragan, I. K., Pardo, C. A., Bowen, R., Zhong, D., Norris, D. E., Ruczinski, I., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49461-0 · Cited by 16

The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19

Barrantes, F. J. (2021) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-102620-080956 · Cited by 15

Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity

Wu, J., Liang, B.-Y., Fang, Y., Wang, H., Yang, X., Shěn, S., Chen, L., Li, S., Lu, S., Xiang, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722027 · Cited by 16

Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines

Wisnewski, A. V., Redlich, C. A., Kamath, K., Abad, Q.-A., Smith, R., Fazen, L. E., Santiago, R., Liu, J., Luna, J. C., Martinez, B., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252849 · Cited by 16

Long Term Immune Response Produced by the SputnikV Vaccine

Martynova, E. V., Hamza, S., Garanina, E. E., Kabwe, E., Markelova, M., Shakirova, V. G., Хаертынова, И. М., Kaushal, N., Baranwal, M., Rizvanov, A. A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011211 · Cited by 18

The Severity of COVID-19 and Its Determinants: A Systematic Review and Meta-Analysis in China

Zhang, N., Xie, T., Wei, N., He, R., Zhu, B., & Mao, Y. (2021) · Sustainability · doi:10.3390/su13095305 · Cited by 15

State of the Art in Epitope Mapping and Opportunities in COVID-19

Hamed, S. M., Sakr, M. M., El-Housseiny, G. S., Wasfi, R., & Aboshanab, K. M. (2023) · Future Science OA · doi:10.2144/fsoa-2022-0048 · Cited by 16

Can BCG vaccine protect against COVID‐19 via trained immunity and tolerogenesis?

Basak, P., Sachdeva, N. K., & Dayal, D. (2020) · BioEssays · doi:10.1002/bies.202000200 · Cited by 15

SARS‐CoV‐2 infection as a trigger of humoral response against apolipoprotein A‐1

Pagano, S., Yerly, S., Meyer, B., Juillard, C., Suh, N., Terrier, C. L., Daguer, J., Soler, L. F., Barluenga, S., Piumatti, G., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13661 · Cited by 15

Predicted B Cell Epitopes Highlight the Potential for COVID-19 to Drive Self-Reactive Immunity

Moody, R., Wilson, K., Boer, J. C., Holien, J. K., Flanagan, K. L., Jaworowski, A., & Plebanski, M. (2021) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2021.709533 · Cited by 14

Functional Analysis of Human and Feline Coronavirus Cross-Reactive Antibodies Directed Against the SARS-CoV-2 Fusion Peptide

Vanderheijden, N., Stevaert, A., Xie, J., Ren, X., Barbezange, C., Noppen, S., Desombere, I., Verhasselt, B., Geldhof, P., Vereecke, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790415 · Cited by 12

IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity

Wang, J., Li, D., Cameron, A., Zhou, Q., Wiltse, A., Nayak, J. L., Pecora, N., & Zand, M. S. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac022 · Cited by 17

Genetic and Structural Analysis of SARS-CoV-2 Spike Protein for Universal Epitope Selection

Markosian, C., Staquicini, D. I., Dogra, P., Dodero‐Rojas, E., Lubin, J. H., Tang, F. H. F., Smith, T. L., Contessoto, V. G., Libutti, S. K., Wang, Z., et al. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msac091 · Cited by 15

The humoral immune response more than one year after SARS-CoV-2 infection: low detection rate of anti-nucleocapsid antibodies via Euroimmun ELISA

Paul, G., Strnad, P., Wienand, O., Krause, U., Plecko, T., Effenberger-Klein, A., Giel, K. E., Junne, F., Galante-Gottschalk, A., Ehehalt, S., et al. (2022) · Infection · doi:10.1007/s15010-022-01830-x · Cited by 17

Association of Cytomegalovirus Serostatus With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responsiveness in Nursing Home Residents and Healthcare Workers

Freeman, M. L., Oyebanji, O. A., Moisi, D. D., Payne, M., Sheehan, M. L., Balazs, A. B., Bosch, J., King, C. L., Gravenstein, S., Lederman, M. M., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad063 · Cited by 18

Serodominant SARS-CoV-2 Nucleocapsid Peptides Map to Unstructured Protein Regions

Vandervaart, J. P., Inniss, N. L., Ling-Hu, T., Minasov, G., Wiersum, G., Rosas‐Lemus, M., Shuvalova, L., Achenbach, C. J., Hultquist, J. F., Satchell, K. J. F., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00324-23 · Cited by 15

CRESSP: a comprehensive pipeline for prediction of immunopathogenic SARS-CoV-2 epitopes using structural properties of proteins

An, H., Eun, M., Yi, J., & Park, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac056 · Cited by 16

Immunity against seasonal human coronavirus OC43 mitigates fatal deterioration of COVID-19

Yamaguchi, T., Shinagawa, T., Kobata, H., & Nakagawa, H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.015 · Cited by 14

Comprehensive analysis of TCR repertoire of COVID-19 patients in different infected stage

Wang, G., Wang, Y., Jiang, S., Fan, W., Mo, C., Gong, W., Chen, H., He, D., Huang, J., Ou, M., et al. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01261-w · Cited by 14

Antibody-mediated spike activation promotes cell-cell transmission of SARS-CoV-2

Yu, S., Zheng, X., Zhou, Y. R., Gao, Y., Zhou, B., Zhao, Y., Li, T., Li, Y., Mou, J., Cui, X., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011789 · Cited by 15

What makes SARS‐CoV‐2 unique? Focusing on the spike protein

Qian, J., Zhang, S.-C., Wang, F., Li, J., & Zhang, J. (2024) · Cell Biology International · doi:10.1002/cbin.12130 · Cited by 16

Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients

Garanina, E. E., Hamza, S., Stott-Marshall, R. J., Martynova, E. V., Markelova, M., Davidyuk, Y. N., Shakirova, V. G., Kaushal, N., Baranwal, M., Хаертынова, И. М., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.842232 · Cited by 13

Machine-learning-aided multiplexed nanoplasmonic biosensor for COVID-19 population immunity profiling

Beisenova, A., Adi, W., Bashar, S. J., Velmurugan, M., Germanson, K. B., Shelef, M. A., & Yesilköy, F. (2023) · Sensors & Diagnostics · doi:10.1039/d3sd00081h · Cited by 14

Applications of VirScan to broad serological profiling of bat reservoirs for emerging zoonoses

Ruhs, E. C., Chia, W. N., Foo, R., Peel, A. J., Li, Y., Larman, H. B., Irving, A. T., Wang, L., & Brook, C. E. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1212018 · Cited by 14

The Influence of Cross-Reactive T Cells in COVID-19

Eggenhuizen, P. J., & Ooi, J. D. (2024) · Biomedicines · doi:10.3390/biomedicines12030564 · Cited by 14

Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics

Zhang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34577 · Cited by 13

Differential pre-pandemic breast milk IgA reactivity against SARS-CoV-2 and circulating human coronaviruses in Ugandan and American mothers

Egwang, T. G., Owalla, T. J., Okurut, E., Apungia, G., Fox, A., Carlo, C. D., & Powell, R. L. R. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.039 · Cited by 12

Escherichia coli recombinant expression of SARS-CoV-2 protein fragments

McGuire, B. E., Mela, J. E., Thompson, V. C., Cucksey, L. R., Stevens, C. E., McWhinnie, R. L., Winkler, D. F. H., Pelech, S., & Nano, F. E. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01753-0 · Cited by 13

Antibody Response to the SARS-CoV-2 Spike and Nucleocapsid Proteins in Patients with Different COVID-19 Clinical Profiles

Soares, S. R., Torres, M. K. D. S., Lima, S. S., de Sarges, K. M. L., dos Santos, E. F., de Brito, M. T. F. M., da Silva, A. L. S., Leite, M. D. M., da Costa, F. P., Cantanhede, M. H. D., et al. (2023) · Viruses · doi:10.3390/v15040898 · Cited by 13

Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach

Uttamrao, P. P., Sathyaseelan, C., Patro, L. P. P., & Rathinavelan, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692937 · Cited by 14

IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes

Garrido, J. L. V., Medina, M. A., Bravo, F., McGee, S., Fuentes‐Villalobos, F., Calvo, M. A., Pinos, Y., Bowman, J. W., Bahl, C. D., Barría, M. I., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110904 · Cited by 13

2.5 Million Person-Years of Life Have Been Lost Due to COVID-19 in the United StatesPreprint

Elledge, S. (2020) · medRxiv · doi:10.1101/2020.10.18.20214783 · Cited by 10

Human ELISA Detects anti-SARS-CoV-2 Antibodies in Cats: Seroprevalence and Risk Factors for Virus Spread in Domestic and Stray Cats in Bulgaria

Sirakov, I. N., Rusenova, N., Rusenov, A. G., Gergova, R. T., & Strateva, T. (2023) · Veterinary Sciences · doi:10.3390/vetsci10010042 · Cited by 12

Can T Cells Abort SARS-CoV-2 and Other Viral Infections?

Swadling, L., & Maini, M. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054371 · Cited by 13

serosim: An R package for simulating serological data arising from vaccination, epidemiological and antibody kinetics processes

Menezes, A., Takahashi, S., Routledge, I., Metcalf, C. J. E., Graham, A. L., & Hay, J. A. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011384 · Cited by 10

An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines

Utomo, D. I. S., Suhaimi, H., Azami, N. A. M., Azmi, F., Amin, M. C. I. M., & Xu, J. C. (2023) · Vaccines · doi:10.3390/vaccines11091506 · Cited by 12

Infection, inflammation and thrombosis: a review of potential mechanisms mediating arterial thrombosis associated with influenza and severe acute respiratory syndrome coronavirus 2

Veizades, S. A., Tso, A., & Nguyen, P. K. P. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0348 · Cited by 12

Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community

Guarino, C., Larson, E. M., Babasyan, S., Rollins, A., Joshi, L. R., Laverack, M. A., Parrilla, L., Plocharczyk, E. F., Diel, D. G., & Wagner, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262868 · Cited by 12

Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses

Pacheco-Olvera, D. L., Remy-Hernández, S. S., García-Valeriano, M. G., Rivera-Hernández, T., & López-Macías, C. I. R. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.10.007 · Cited by 12

T cell control of SARS-CoV-2: When, which, and where?

Diniz, M. O., Maini, M. K., & Swadling, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101828 · Cited by 12

COVID-19: cross-immunity of viral epitopes may influence severity of infection and immune response

Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00490-x · Cited by 12

Effect of Cytomegalovirus on the Immune System: Implications for Aging and Mental Health

Ford, B. N., & Savitz, J. B. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_376 · Cited by 12

Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study

Ashworth, J., Mathie, D., Scott, F., Mahendran, Y., Woolhouse, M. E. J., Stoevesandt, O., Mduluza, T., & Mutapi, F. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00295-6 · Cited by 12

Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations

Yalcin, D., Bennett, S. J., Sheehan, J., Trauth, A. J., Tso, F. Y., West, J. T., Hagensee, M. E., Ramsay, A. J., & Wood, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087292 · Cited by 11

Identifying the geospatial relationship of surface ozone pollution in China: Implications for key pollution control regions

Cheng, Y., Yan, P., Cao, L., Huang, X., & He, L. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.172763 · Cited by 12

Adaptive immune responses to SARS-CoV-2

Forthal, D. N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.009 · Cited by 11

Using secondary cases to characterize the severity of an emerging or re-emerging infection

Tsang, T. K., Wang, C., Yang, B., Cauchemez, S., & Cowling, B. J. (2021) · Nature Communications · doi:10.1038/s41467-021-26709-7 · Cited by 11

Deep dissection of the antiviral immune profile of patients with COVID-19

Atanackovic, D., Avila, S. V., Lutfi, F. U., de Miguel‐Pérez, D., Fan, X., Sanchez‐Petitto, G., Mause, E. R. V., Siglin, J., Baddley, J. W., Mannuel, H. D., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02852-1 · Cited by 10

Conserved Pattern and Potential Role of Recurrent Deletions in SARS-CoV-2 Evolution

Weng, S., Zhou, H., Ji, C., Li, L., Han, N., Yang, R., Shang, J., & Wu, A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02191-21 · Cited by 11

Immunogenic SARS-CoV-2 S and N Protein Peptide and Cytokine Combinations as Biomarkers for Early Prediction of Fatal COVID-19

Martynova, E. V., Hamza, S., Markelova, M., Garanina, E. E., Davidyuk, Y. N., Shakirova, V. G., Kaushal, N., Baranwal, M., Stott-Marshall, R. J., Foster, T. L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830715 · Cited by 11

Human seasonal coronavirus neutralization and COVID‐19 severity

Wells, D. A., Cantoni, D. M., Neto, M. M., Genova, C. D., Sampson, A., Ferrari, M., Carnell, G., Nadesalingam, A., Smith, P., Chan, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27937 · Cited by 12

Linear epitope mapping of the humoral response against SARS-CoV-2 in two independent African cohorts

Vigan-Womas, I., Spadoni, J., Poiret, T., Taieb, F., Randrianarisaona, F., Faye, R., Mbow, A. A., Gaye, A., Dia, N., Loucoubar, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27810-1 · Cited by 11

High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients

Sejdic, A., Frische, A., Jørgensen, C. S., Rasmussen, L. D., Trebbien, R., Dungu, A. M., Holler, J. G., Ostrowski, S. R., Eriksson, R., Søborg, C., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-01974-8 · Cited by 11

Unravelling Antigenic Cross-Reactions toward the World of Coronaviruses: Extent of the Stability of Shared Epitopes and SARS-CoV-2 Anti-Spike Cross-Neutralizing Antibodies

Devaux, C. A., & Fantini, J. (2023) · Pathogens · doi:10.3390/pathogens12050713 · Cited by 11

Signatures of AAV-2 immunity are enriched in children with severe acute hepatitis of unknown etiology

Mitchell, M., Leng, Y., Boppana, S. B., Britt, W. J., Sanchez, L. H. G., & Elledge, S. J. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh9917 · Cited by 11

Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study

Zurochka, A., Dobrinina, M., Александрович, З. В., Hu, D., Solovyov, A. I., Ryabova, L. V., Kritsky, I. S., Ibragimov, R., & Sarapultsev, A. (2021) · Vaccines · doi:10.3390/vaccines9060627 · Cited by 11

Mapping the SARS-CoV-2 Epitope Landscape and Uncovering the Origins of Immunodominant Public Epitopes

Shrock, E. L. (2023) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)

ELISA-Based Analysis Reveals an Anti-SARS-CoV-2 Protein Immune Response Profile Associated with Disease Severity

Herrscher, C., Eymieux, S., Gaborit, C., Blasco, H., Marlet, J., Stéfic, K., Roingeard, P., Grammatico‐Guillon, L., & Hourioux, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020405 · Cited by 6

Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity

Amrun, S. N., Lee, C. Y., Lee, B. T. K., Fong, S., Young, B. E., Chee, R. S., Yeo, N. K., Torres‐Ruesta, A., Carissimo, G., Poh, C. M., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102911 · Cited by 142

SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients

Schwarz, T., Heiß, K., Mahendran, Y., Casilag, F., Kurth, F., Sander, L. E., Wendtner, C., Hoechstetter, M. A., Müller, M. A., Sekul, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629185 · Cited by 45

Binding signatures and cross-reactivity in the SARS-CoV-2 immune response

Stoddard, C. I., Galloway, J., Chu, H., Shipley, M. M., Sung, K. Y., Itell, H. L., Wolf, C. R., Logue, J. K., Magedson, A., Garrett, M. E., et al. (2021) · Topics in antiviral medicine